Digital Therapeutics (DTx) in Germany: Pioneering “Deutsche Gründlichkeit” with Quality by Design
Digital Therapeutics (DTx) in Germany: Pioneering “Deutsche Gründlichkeit” with Quality by Design
Regulatory Affairs Software Solutions & Services Medical Devices In Vitro Diagnostics
Wednesday, 28 February 2024
QbD Group
Share
\
\
X (Twitter) 
\
\
LinkedIn 
\
\
WhatsApp 
\
\
Copy link 
\
\
Mail
When it comes to the regulation of Digital Therapeutics (DTx), Germany is pioneering new paths for its adoption. This blog post delves into the intricacies of Germany's approach to DTx regulation.
Play
Digital Therapeutics (DTx) in Germany: Pioneering “Deutsche Gründlichkeit” with Quality by Design | QbD Group
AI-generated audio
3:58
Germany has always been renowned for its meticulous attention to detail, often described by the term ‘Deutsche Gründlichkeit’. It’s no wonder then, that when it comes to the regulation of Digital Therapeutics (DTx), Germany is pioneering new paths for its adoption.
While all Digital Therapeutics must adhere to the foundational EU requirements for CE marking (as detailed in our previous blog post on the ‘EU regulatory landscape’), Germany goes a step further. The country has formulated its own national laws addressing DTx patient safety, data protection, and even a prescription and reimbursement approval process.
This blog post delves into the intricacies of Germany’s approach to DTx regulation.
Deciphering DiGA: Germany’s definition of DTx
Germany’s definition of DTx, referred to as DiGAs in German, is crystal clear:
- It is a specific CE-marked medical device.
- It relies predominantly on digital technologies for its primary function.
- Its digital features drive its medical purpose.
- DiGA can be utilized either by patients independently or in collaboration with healthcare providers.
In essence, one could say: ‘ DiGA is akin to a digital assistant at a patient’s fingertips’.
Free whitepaper
Mobile Health on the Rise
This whitepaper will help you navigate the intricate maze of the current DTx regulatory environment, highlighting several important countries and regulations.
The DiGA Fast-Track Procedure through quality by design
Germany’s innovative approach is further evident in its fast-track procedure, which facilitates swift approval, testing, and reimbursement for DiGAs. This streamlined procedure, which spans merely 15 months, aims to make these solutions available to Germany’s 73 million insured citizens.
The magic of this fast-track procedure lies in its early-stage engagement. Right from the outset, developers and authorities collaborate closely, ensuring that every proposed application is meticulously vetted. Applications are assessed for their genuine value to national health, with greenlit projects being pursued jointly.
This “quality by design” approach is transformative. It emphasizes early identification of evidence requirements, leading to minimal design alterations. With comprehensive data privacy and operational efficiency checks, this ensures a cost-effective, highly efficient pathway to reimbursement approval.
Navigating the German Regulatory Landscape
For those looking for a comprehensive guide, the ‘Digital Healthcare’ Act ( DVG) and the ‘Digital Health Applications Ordinance ( DiGAV)’ are invaluable. Instituted between 2019 and 2020, these laws encapsulate data protection measures and quality and safety protocols. They align with the European Regulation (EU) 2017/745 on medical devices and provide clarity on prescription and reimbursement at a national level.
Since the initiation of these laws, there has been significant adoption. By October 2020, the first DiGA product was approved, and as of now, 53 BfArm-endorsed “apps on prescription” (DiGAs) are available for doctors to prescribe.
For those keen on leveraging the fast-track procedure, the Health Authority website (BfArm) is a treasure trove of resources, detailing the legal framework and providing tools to demystify the process.
In summary, an “app on prescription” in Germany:
- Adheres to the Medical Device Regulation (MDR) or the transitional Medical Device Directive (MDD). When is an app a medical device? Find out here.
- Harnesses digital technologies as its central function.
- Achieves its medical objectives predominantly via its digital capabilities.
- Aids in diagnosing, monitoring, and treating diseases or injuries.
- Can be utilized by patients alone or in tandem with healthcare providers.
- Successfully passes the BfArm assessment.
It’s worth noting that as the digital health landscape evolves, so will the Digital Healthcare Act, with proposed changes being regularly updated on the BfArm website.
Conclusion
In the realm of Digital Therapeutics, Germany is a trendsetter. Their forward-thinking DiGA fast-track procedure exemplifies the synergy between the private sector and authorities, delivering unparalleled cost savings and efficiency. With Germany’s trailblazing efforts, other nations like Belgium and France are following suit. In the next blog posts, we delve deeper into these developments.
Want to stay up to date with all the latest developments and innovations in DtX? Subscribe to our newsletter.
Need regulatory support?
Trust our expertise to guide you through the regulatory process and achieve compliance
with ease.
Discover how we can help.
Need Qualification & Validation support?
Qualification and validation are essential to ensuring your systems perform flawlessly.
Ready to enhance your processes?
Explore our solutions.
Stay ahead in life sciences
Keeping up with the fast-paced life sciences industry doesn’t have to be overwhelming.
Our newsletter delivers the latest insights, industry updates, and expert content directly to your inbox, helping you stay informed and make smarter decisions.
Discover more expert content
Webinar
From Strategy to First-in-Human: A Practical Roadmap for Biotech Development
Join our webinar to learn how to navigate nitrosamine risks and streamline your biotech development from early planning to first-in-human trials. Register now for expert insights.
Webinar
PMS & PMCF Compliance for Medical Devices Under EU MDR
Gain practical insights on PMS & PMCF compliance for medical devices under EU MDR. Watch our webinars on demand.
Case study
A Decade of Excellence: Linguistic Review Support for a Global Pharma Leader
QbD Group streamlines linguistic reviews for a leading pharma client, ensuring compliance and accuracy across 25 EU/EEA languages while meeting stringent regulatory deadlines.
Case study
Supporting Market Access to Essential Medicines in Europe
Support your entry into the European pharmaceutical market with expert regulatory guidance, ensuring compliance and access to essential medicines for patients. Contact us today for assistance.
%20Checklist.jpg)
Whitepaper
Medical Device Regulation (MDR) Checklist
Implement the Medical Device Regulation (MDR) with ease. Download our checklist of mandatory documents for MDR compliance.
Whitepaper
Regulatory Affairs for Pharma and Biotech
In this flyer, you will learn more about the regulatory services QbD Group provides for the pharmaceutical and biotechnology industries.
Whitepaper
Clinical Evaluation for Medical Devices under MDR
This whitepaper will guide you through crucial regulatory documents pertaining to the clinical evaluation process of your medical device. Download now!
Whitepaper
IVDR extension: what does this mean for you?
In this whitepaper, you will learn the impact of the IVDR transition extension and receive tips and strategies to navigate these regulatory changes.
Webinar
Drug-Device Combination Products and Article 117
Explore the regulatory complexities of Drug-Device Combination Products. Learn about Article 117 requirements, Notified Body Opinions, and more.
Whitepaper
Mobile health on the rise: exploring the regulatory landscape for reimbursement
This whitepaper will help you navigate the maze of the DTx regulatory environment, highlighting several important countries and regulations.
Whitepaper
Clinical investigations under MDR: key insights and practical experiences
This whitepaper covers clinical investigation authorization under MDR, the EU Legal Representative's role, and the MDR's impact on study conduct and post-market surveillance.
Case study
CE Mark Renewal for bioXtra Products: A Success Story
Discover how Lifestream Pharma successfully renewed the CE mark for their BioXtra Dry Mouth products under the EU MDR. Learn about the challenges faced, the approach taken for compliance, and the results achieved.
Webinar
Technical Documentation Essentials for Medical Device Software
Gain practical insights on crafting MDR-compliant technical documentation for Medical Device Software.
.jpg)
Webinar
Getting Started: Overcoming Initial Obstacles in Medical Device Software Development
Watch our webinar on demand and learn about regulatory obstacles, MDR, AI Act, and best practices for medical device software development and market entry.
Webinar
Mastering Clinical Performance Studies under IVDR
In the evolving regulatory landscape of IVDs, demonstrating clinical performance is more crucial and challenging than ever. Discover more in this webinar on demand.
Whitepaper
Clinical evidence for In Vitro Diagnostics under IVDR
In this whitepaper, we will guide you through the documents required for the demonstration of clinical evidence under the IVDR. Download now.
Webinar
Post-Market Surveillance Requirements for Medical Devices and IVDs
Learn about post-market surveillance requirements under MDR and IVDR regulations. Gain insights from industry experts in this on-demand webinar.
Whitepaper
The key role of Regulatory Affairs in the pharmaceutical industry: from drug development to commercialization
Discover the key role of Regulatory Affairs in pharma and how Regulatory Affairs teams support product lifecycle management in this whitepaper. Download now.
.jpg)
Webinar
3D Printing in the Healthcare World
Explore the challenges and opportunities of 3D printing in healthcare, featuring expert insights on regulations, pitfalls, and efficiency.
.jpg)
Webinar
IVDR Extension Explained: Tips & Strategies
Gain valuable insights on the IVDR extension and its impact on IVD manufacturers with our webinar on demand.
Whitepaper
Innovations in ATMP: state of the industry in 2024
This whitepaper explores the innovations in ATMP and solutions in detail, with a focus on the current landscape as of April 2024. Download now.
.jpg)
Case study
The journey toward IVDR compliance for the LVOne device
QbD Group helped Upfront Diagnostics gain entry into the MD/IVD industry by supporting them on their path to ISO 13485 certification.
Case study
Ensuring a smooth MDR transition for Oystershell's medical devices
The landscape of medical device regulations is constantly evolving, making it a challenge for companies to keep up. Our collaboration with Oystershell, which began in July 2023, highlights our expertise in transforming complex challenges into success stories, all with a touch of QbD Clinical magic.
Case study
Successful clinical evaluation supports rapid CE marking of Minze Health's Uroflowmeter
QbD Clinical assisted Minze Health, a urology-focused medical devices company, in obtaining CE marking under MDR through clinical evaluation.
.jpg)
Webinar
The Medical Device CE Certification Pathway Explained: From Classification to Conformity Assessment by the Notified Body
Learn about the Medical Device CE Certification Pathway, from classification to conformity assessment by a Notified Body. Join our webinar on demand.
.jpg)
Case study
Helping Relu to comply with changing regulations
QbD Group supported software company Relu with their expertise to comply with changing regulations.
.png)
Case study
Quickly bringing a new COVID-19 medical device to market
Obtaining the required government certifications for a medical device is always a challenge. Especially when the COVID clock is ticking.
Twitter Widget Iframe